Furthermore, unlike chymase inhibitors, ACE inhibitors and ARBs currently in clinical use do not inhibit the activation of TGF-β and MMP-2, suggesting that chymase could serve as a novel therapeutic target for cardiac remodeling in conditions such as heart failure. This evidence concerns the gene TGFB1 and heart failure.